Clinical trials: Pharynx Carcinoma
Nasopharyngeal Carcinoma
A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients
To investigate the efficacy of adjuvant PFL chemotherapy after radiotherapy vs radiotherapy alone in AJC stage IV nasopharyngeal carcinoma patients.
- Trial name
- NCT00201344
- Testing
- Cisplatin,5-FU,Leucovorin
- Where
- Taiwan
- Volunteers
- 320 people
- Sponsor
- National Health Research Institutes, Taiwan
Surgery, Recurrent Nasopharyngeal Carcinoma
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a randomized controlled trial of…
- Trial name
- NCT04425265
- Testing
- Plasma radiofrequency ablation, Electrocautery block resection
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a single-arm, open-label, multicenter, phase II study to evaluate the anti-tumor activity, PK and immunogenicity of AK104 in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior…
- Trial name
- NCT04220307
- Testing
- AK104
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Akeso
Nasopharyngeal Carcinoma
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally…
- Trial name
- NCT06059261
- Testing
- Envafolimab and recombinant human endostatin combined with chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Nasopharyngeal Neoplasms
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients
A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma…
- Trial name
- NCT02505139
- Testing
- the number of circulating tumor cells
- Volunteers
- 166 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma
this study is aimed to evaluate the efficacy and safety of the combination of Niraparib and Sintilimab in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05162872
- Testing
- Niraparib，Sintilimab
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Sun Yat-sen University
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy
To evaluate the sensitivity and specificity of the combination of EBV and methylation marker genes in body fluids of both plasma and nasopharyngeal brush together for screening of early salvageable local residual and recurrent…
- Trial name
- NCT03379610
- Testing
- Nasopharngeal brush
- Volunteers
- 426 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma
A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
The goal of this clinical trial is to compare the efficacy and safety of curative radiotherapy with or without induction chemotherapy in patients with T3N1M0 nasopharyngeal carcinoma.
- Trial name
- NCT05622474
- Testing
- Induction chemotherapy plus Concurrent chemotherapy, Concurrent chemotherapy, IMRT
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma
Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy
Non-commercial clinical study to assess: 1. efficacy of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma. 2.
- Conditions
- Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma, Larynx Carcinoma, Paranasal Sinus Carcinoma
- Trial name
- iCHRTL (NCT05992610)
- Testing
- Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Nasopharyngeal Carcinoma, Maintenance Therapy
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
The aim of this study is to investigate the efficacy and safety of the "capecitabine combined with toripalimab maintenance regimen" in improving the first-line treatment of recurrent and metastatic nasopharyngeal carcinoma after…
- Trial name
- NCT05869227
- Where
- China
- Volunteers
- 166 people
- Sponsor
- XIANG YANQUN
Nasopharyngeal Carcinoma
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and…
- Trial name
- NCT06383780
- Testing
- GP combined with Tislelizumab, TPC combined with Tislelizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- XIANG YANQUN
Nasopharyngeal Carcinoma, Recurrent or Metastatic
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST…
- Trial name
- NCT03848286
- Testing
- KL-A167 Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Locally Advanced Malignant Neoplasm, Oral Cancer
Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Epidermal growth factor receptor（EGFR） is a potential target for new anticancer therapy in head and neck squamous cell carcinoma, because blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the…
- Conditions
- Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma
- Trial name
- NCT01440270
- Testing
- Neo-adjuvant Erbitux-based chemotherapy
- Where
- 7 sites in China
- Volunteers
- 145 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Nasopharyngeal Carcinoma
Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients
The investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC. Furthermore, the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by…
- Trial name
- NCT06442709
- Testing
- Tocilizumab Asprin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Hospital of Nantong University
Dysphagia
Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06265844
- Testing
- Intermittent Oral-esophageal Tube Feeding, Nasogastric Tube Feeding, comprehensive rehabilitation therapy
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Zeng Changhao
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
- Trial name
- NCT06319963
- Testing
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Theravectys S.A.
Nasopharyngeal Carcinoma
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma
To see the effect of induction chemotherapy（TPF） followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy (PF) in treating patients with high risk nasopharyngeal carcinoma…
- Trial name
- NCT03306121
- Testing
- TPF+CCRT, CCRT+ PF
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive…
- Trial name
- NCT07552558
- Testing
- Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.